Save Dihexa is an angiotensin-IV-derived oligopeptide marketed as a research nootropic, and its honest safety picture starts with an absence: there are no published human clinical trials of Dihexa, and therefore no human safety, toxicology, or pharmacokinetic data of any kind
Phase 3 clinical trials are underway, with promising results beyond even weight loss
Data Availability Not applicable
2017 study reported improvements in aged mice that were sustained through the observation period, suggesting that senescent cell clearance produces durable benefits once senescent cells are eliminated, their pro-inflammatory SASP burden is removed, allowing tissue recovery that persists beyond the treatment window
ESIMS calculated [m/z] for C 27 H 29 N 6 O + [(M + H) + ] is 453.2, and observed 453.1
In the original studies included in this review, experiments using longer single sessions (e.g., 60 min of walking or power cycling) often reported smaller or statistically non-significant cognitive effects, whereas experiments using moderate-duration exercise of 3040 min yielded better outcomes